Former X CEO and senior NBCUniversal executive Linda Yaccarino has been named CEO of digital weight-loss firm eMed.

Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

(Reuters) -Shares of Hims & Hers fell nearly 9% on Tuesday after the telehealth firm reported weaker-than-expected quarterly revenue, in part as its move from branded to lower-cost, personalized ...

The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

Online telehealth company Hims and Hers Health missed Wall Street estimates for second-quarter revenue on Monday, as it lost subscribers for compounded versions of weight-loss drugs, sending its ...

GLP-1s (glucagon-like peptide-1 receptor agonists), like Wegovy, Ozempic, or generic liraglutide, have helped you reach your ...

Medical professionals observe that GLP-1 medications like Ozempic show promise for treating rheumatoid arthritis alongside other inflammatory conditions.

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

In 568 patients who underwent bariatric surgery, those who also used a GLP-1 receptor agonist during the preoperative and postoperative period experienced significantly greater weight loss -- a 33% ...